CD8A and cancer: Subsequently, the first human cancer antigen, melanoma-associated antigen 1, was recognized in 19914, and genetically modified whole cell tumor vaccines with the secretion of granulocyte-macrophage colony-stimulating factor were shown to elicit a specific CD8+ T cell response in 19935.